EloxiOral (Meloxicam) for Dogs | On Sale | EntirelyPets Rx
Licensed U.S. Pet Pharmacy | Verified Pharmacy

EloxiOral Oral Suspension for Dogs

Item#
FREE SHIPPING Over $49! * Pet Food & Other Exclusions
1. Select size:
QTY:-+

Price too low to show

Add to cart to see low price
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
$16.99Reg $22.09
$32.99Reg $42.89
$69.99Reg $90.99
  • Description
  • Directions
  • FAQ
  • Reviews

Description

EloxiOral is a non-steroidal anti-inflammatory drug (NSAID) that is used to control pain and inflammation (soreness) due to osteoarthritis in dogs. Osteoarthritis (OA) is a painful condition caused by "wear and tear" of cartilage and other parts of the joints that may result in the following changes or signs in your dog: Limping or lameness, decreased activity or exercise. Meloxicam, is administered through a syringe or mixed with food and its effects are comparable to Metacam and Meloxidyl.

Key Benefits

  • Effective control of symptoms of OA in dogs
  • Conveniently packaged with small and large syringes for use with any size dog
  • Easy adminstration directly through the mouth or by mixing with food
  • Affordable alternative to Metacam

Indications

EloxiOral Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Prescription Required

Directions

View EloxiOral Oral Suspension Drug Facts Sheet.

Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of EloxiOral Oral Suspension and other treatment options before deciding to use EloxiOral Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. EloxiOral Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day, EloxiOral Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg). The syringes are calibrated to deliver the daily maintenance dose in lbs. Because the first dose (0.2 mg/kg) is two times the amount of the daily maintenance dose (0.1 mg/kg), two syringes containing the 0.1 mg/kg dose should be administered at the first dose.

EloxiOral Oral Suspension is packaged with 2 sizes of dosing syringes. The small syringe is calibrated in 1-lb increments for use in dogs under 30 lbs. The large syringe is calibrated in 5-lb increments (up to 160 lbs) and should be used for dosing dogs that are 30 lbs and over. Only administer EloxiOral with the provided syringes. The container should never be used as a dropper bottle for administration of EloxiOral.

Dog under 30 lbs (13.6 kg): Shake well before use, then remove cap. EloxiOral Oral Suspension can be given either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. To prevent accidental overdosing of small dogs, only use the small dosing syringe. The large syringe provided should not be used to measure doses for dogs weighing less than 30 lbs (13.6 kg). For dogs under 30 lbs, use the small dosing syringe provided in the package (see dosing procedure below). The small dosing syringe fits onto the bottle and has dosing marks in 1-lb increments, designed to deliver the daily maintenance dose of 0.045 mg/lb (0.1 mg/kg). For dogs between 1-29 lbs, EloxiOral can be given using the marks on the small dosing syringe. When using the small dosing syringe, the dog's weight should be rounded down to the nearest 1-lb increment. Replace and tighten cap after use.

Dogs 30 lbs (13.6 kg) and over: Shake well before use, then remove cap. EloxiOral may be either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. To prevent accidental overdosing of small dogs, do not use the large syringe in animals weighing less than 30 pounds. For dogs 30 lbs or greater, the large dosing syringe provided in the package should be used (see dosing procedure below). The large dosing syringe fits onto the bottle and has dosing marks in 5-lb increments (up to 160 lbs), designed to deliver the daily maintenance dose of 0.045 mg/lb (0.1 mg/kg). When using the large syringe, the dogs weight should be rounded down to the nearest 5-lb increment. Replace and tighten cap after use.

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Contraindications

Dogs with known hypersensitivity to meloxicam should not receive EloxiOral Suspension. Do not use EloxiOral Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Warnings

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only.

As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about EloxiOral.

Precautions

The safe use of EloxiOral Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient.

Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after administration of the total daily dose of EloxiOral Oral Suspension, a non-NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with EloxiOral Oral Suspension has not been studied in dogs.

Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of EloxiOral Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

Adverse Reactions

Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappentance) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study.

In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog).

Adverse Reactions Observed During Two Field Studies
Clinical Observation Meloxicam (n=157) Placebo (n=149)
Vomiting 40 23
Diarrhea/Soft Stool 19 11
Bloody Stool 1 0
Inappetance 5 1
Bleeding gums after dental procedure 1 0
Lethargy/Swollen Carpus 1 0
Epiphora 1 0

Post-Approval Experience (Rev. 2010): The following ad-verse events are based on post-approval adverse drug ex-perience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system.

  • Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration
  • Urinary: azotemia, elevated creatinine, renal failure
  • Neurological/Behavioral: lethargy, depression
  • Hepatic: elevated liver enzymes
  • Dermatologic: pruritus

Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of meloxicam in cats.

To report suspected adverse reactions, to obtain a Material Safety Data Sheet, or for technical assistance, call Henry Schein at 1-855-724-3461. For a complete listing of ad-verse reactions for meloxicam reported to the CVM see: http://www.fda.gov/ADEreports

Information for Dog Owners

EloxiOral, like other drugs of its class, is not free from ad-verse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Re-actions). Owners should be advised to discontinue Elox-iOral and contact their veterinarian immediately if signs of intolerance are observed.

The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owner should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.

Clinical Pharmacology

Meloxicam has nearly 100% bioavailability when administered orally with food. The terminal elimination half life after a single dose is estimated to be approximately 24 hrs (+/-30%) regardless of route of administration. There is no evidence of statistically significant gender differences in drug pharmacokinetics. Drug bioavailability, volume of distribution, and total systemic clearance remain constant up to 5 times the recommended dose for use in dogs. However, there is some evidence of enhanced drug accumulation and terminal elimination half life prolongation when dogs are dosed for 45 days or longer.

Peak drug concentrations can be expected to occur within about 7.5 hrs after oral administration. Corresponding peak concentration is approximately 0.464 mcg/mL following a 0.2 mg/kg oral dose. The drug is 97% bound to canine plasma proteins.

Effectiveness

The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between sic months and sixteen years of age, all diagnosed with osteoarthritis. Both of the placebo controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters evaluated by veterinarians included lameness, weight bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement.

In the first field study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second field study (n=48), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14.

Safety

Six Week Study: In a six week target animal safety study, meloxicam was administered orally at 1, 3, and 5X the recommended dose with no significant clinical adverse reactions. Animals in all dose groups (control, 1, 3 and 5X recommended dose) exhibited some gastrointestinal distress (diarrhea and vomiting). No treatment related changes were observed inhematological, blood chemistry, urinalysis, clotting time, or buccal mucosal bleeding times. Necropsy results included stomach mucosal petechiae in one control dog, two dogs at the 3X and one dog at the 5X dose. Other macroscopic changes included areas of congestion or depression of the mucosa of the jejunum or ileum in three dogs at the 1X dose and in two dogs at the 5X dose. Similar changes were also seen in two dogs in the control group. There were no macroscopic small intestinal lesions observed in dogs receiving the 3X dose. Renal enlargement was reported during the necropsy of two dogs receiving the 3X and two receiving the 5X dose.

Microscopic examination of the kidneys revealed minimal degeneration or slight necrosis at the tip of the papilla in three dogs at the 5X dose. Microscopic examination of the stomach showed inflammatory mucosal lesions, epithelial regenerative hyperplasia or atrophy, and submucosal gland inflammation in two dogs at the recommended dose, three dogs at the 3X and four dogs at the 5X dose. Small intestinal microscopic changes included minimal focal mucosal erosion affecting the villi, and were sometimes associated with mucosal congestion. These lesions were observed in the ileum of one control dog and in the jejunum of one dog at the recommended dose and two dogs at the 5X dose.

Six Month Study: In a six month target animal safety study, meloxicam was administered orally at 1, 3, and 5X the recommended dose with no significant clinical adverse reactions. All animals in all dose groups (controls, 1, 3, and 5X the recommended dose) exhibited some gastrointestinal distress (diarrhea and vomiting). Treatment related changes seen in hematology and chemistry included decreased red blood cell counts in seven of 24 dogs (four 3X and three 5X dogs), decreased hematocrit in 18 of 24 dogs (including three control dogs), dose related neutrophilia in one 1X two 3X and three 5X dogs, evidence of regenerative anemia in two 3X and one 5X dog. Also noted were increased BUN in two 5X dogs and decreased albumin in one 5X dog.

Endoscopic changes consisted of reddening of the gastric mucosal surface covering less than 25% of the surface area. This was seen in three dogs at the recommended dose, three dogs at the 3X dose and two dogs at the 5X dose. Two control dogs exhibited reddening in conjunction with ulceration of the mucosa covering less than 25% of the surface area. Gross gastrointestinal necropsy results observed included mild discoloration of the stomach or duodenum in one dog at the 3X and in one dog at the 5X dose. Multifocal pinpoint red foci were observed in the gastric fundic mucosa in one dog at the recommended dose, and in one dog at the 5X dose.

No macroscopic or microscopic renal changes were observed in any dogs receiving meloxicam in this six month study. Microscopic gastrointestinal findings were limited to one dog at the recommended dose, and two dogs at the 3X dose. Mild inflammatory mucosal infiltrate was observed in the duodenum of one dog at the recommended dose. Mild congestion of the fundic mucosa and mild myositis of the outer mural musculature of the stomach were observed in two dogs receiving the 3X dose.

Storage:

Store at controlled room temperature 68-77°F (20-25°C). Excursions permitted between 59°F and 86°F (15°C and 30°C). Brief exposure to temperature up to 104°F (40°C) may be tolerated provided the mean kinetic temperature does not exceed 77°F(25°C); however such exposure should be minimized.

FAQ

Your veterinarian will recommend a treatment plan and may suggest that your dog try EloxiOral for a specific period of time. Your veterinarian may ask you to report back or return with your dog for a follow-up evaluation to determine if treatment should continue. Just like people who have osteoarthritis, your dog will likely have to live with this condition for the rest of his life. You can feel comfortable giving EloxiOral knowing that it has been safely used to treat dogs with osteoarthritis around the world for over 20 years.
EloxiOral targets and relieves both the pain and inflammation caused by osteoarthritis. Relief from arthritis pain can help restore mobility, allowing your dog to return to many of the activities that you both previously enjoyed. Best of all, it can be given once daily, which provides a full 24 hours of relief.
Aspirin is a drug that is not approved for use in animals. Aspirin should not be given during EloxiOral therapy. Also, EloxiOral should not be given with other anti-inflammatory drugs such as cortisone, Rimadyl (carprofen), ibuprofen, Previcox (firocoxib), or Deramaxx (deracoxib). Be sure to tell your veterinarian about any other medications your dog is taking before beginning treatment with EloxiOral.
EloxiOral therapy is one of a number of things that may help relieve your dog's osteoarthritis pain. Your veterinarian may suggest a weight loss program or exercise regimen. Talk to your veterinarian before starting your dog on any weight loss or exercise plan. You can also help to make your dog as comfortable as possible by providing a soft place to sleep and keeping him or her warm. Performing massage and physical therapy on your dog as directed by your veterinarian can relieve joint stiffness and increase range of motion. In addition, raising food and water bowls to avoid neck strain, installing ramps to avoid your dog having to use stairs, putting non-skid runners on slippery surfaces, and other such supportive measures can help make daily activities less painful.
Just as many children's medicines come in liquid rather than pill form, liquid EloxiOral is designed to make it easier to administer the right dose to dogs. EloxiOral Oral Suspension is made in a smooth liquid form so that dog owners can dispense it easily from the syringe. Because it's liquid, it is easy to adjust the dose in small increments using the measuring syringe, with a precision unavailable from a rigid tablet. It is easily applied to the dog's food or given directly into the dog's mouth. Moreover, liquid EloxiOral is readily absorbed by dogs. And, dogs love the sweet honey-flavored taste. EloxiOral, the first NSAID available as an oral suspension, offers a highly convenient treatment option to dog owners and allows for accurate dosing for any size dog'something that chewable tablets cannot always achieve.
Even small-breed dogs get osteoarthritis. That's why a special low-concentration EloxiOral Oral Suspension for small dogs was developed.
Give the missed dose as soon as you remember. However, it is almost time for the next regularly scheduled dose, skip the missed dose and take the next one as directed. Do not give a double dose of the medication.
Seek emergency veterinary medical treatment. Symptoms of EloxiOral overdose include nausea, vomiting, stomach pain, loss of consciousness, drowsiness, headache, cardiac arrest, stomach pain, seizures, little or no urine production, and slow breathing
Many over a counter cough, cold, allergy and pain medicines contain aspirin or other NSAID's similar to EloxiOral. Before taking any prescription or over the counter medications talk to the veterinarian or pharmacist.

Customers Who Bought Also Bought